Oligonucleotide CDMO Market: Growth, Size, Share, and Trends

The expansion of oligonucleotide programs from preclinical research to clinical and commercial stages is strengthening demand for CDMO services. As programs advance, sponsors require partners that can support process development, scale-up, GMP production, and commercial supply. This is particularly important for companies that lack specialized oligonucleotide manufacturing infrastructure. The need for consistent technology transfer and increasing production volumes is further supporting outsourcing. CDMOs with integrated development and manufacturing capabilities can help sponsors manage capacity requirements as programs progress toward commercialization.

The complex manufacturing requirements for therapeutic oligonucleotides remain a major constraint. Multiple synthesis cycles can reduce yields as sequence length and modification levels increase. Purification and impurity control also require extensive analytical testing. Modified backbones, conjugates, and longer sequences further complicate scale-up and technology transfer. These requirements increase manufacturing costs and heighten dependence on specialized equipment, skilled personnel, and validated processes. Maintaining consistent purity and yield across larger batches remains a key challenge for CDMOs.

The growing use of oligonucleotides in CRISPR-Cas9 workflows presents an opportunity for CDMOs as demand rises for high-quality guide RNAs and related components. CRISPR applications require sequence-specific molecules with controlled purity and consistency. Developing complex gene-editing programs can increase demand for specialized synthesis and analytical capabilities. CDMOs with flexible production platforms can support both development-scale material and GMP-grade oligonucleotides. The expansion of gene-editing pipelines is therefore creating opportunities for specialized guide RNA manufacturing.

Maintaining a sustainable supply chain remains a key challenge because oligonucleotide manufacturing relies on specialized phosphoramidites, solvents, reagents, and other critical inputs. Large-scale synthesis also consumes substantial solvents and generates process waste. Supply constraints for critical materials can disrupt production planning and increase costs. As commercial volumes increase, CDMOs face greater requirements for secure sourcing, solvent recovery, waste reduction, and resource efficiency. Building resilient supply networks while improving environmental performance remains challenging as production scales.